WO2025082467 - IMMUNOMODULATORS
National phase entry:
Publication Number
WO/2025/082467
Publication Date
24.04.2025
International Application No.
PCT/CN2024/125698
International Filing Date
18.10.2024
Title **
[English]
IMMUNOMODULATORS
[French]
IMMUNOMODULATEURS
[Chinese]
一种免疫调节剂
Applicants **
HITGEN INC.
Inventors
LI, Jin
BAI, Xiaoguang
HONG, Xinfu
GONG, Yi
DENG, Ning
ZHANG, Pei
QU, Qingxi
HUANG, Xiaodong
ZHANG, Rui
Priority Data
202311355692.7
19.10.2023
CN
202410006918.0
03.01.2024
CN
202410151124.3
02.02.2024
CN
202410954855.1
17.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3412 | |
| EPO | Filing, Examination, Granting | 17820 | |
| Japan | Filing, Examination, Granting | 2109 | |
| South Korea | Filing, Examination, Granting | 2075 | |
| USA | Filing, Examination, Granting | 6090 |
Total:
31,506
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed in the present invention are immunomodulators. Specifically, the present invention relates to compounds that inhibit IL-17A and the use thereof as immunomodulators in the preparation of drugs. Disclosed in the present invention is the use of compounds represented by formula (I) or stereoisomers thereof in the preparation of drugs inhibiting IL-17A, thus providing a new option for clinically screening and/or preparing drugs for diseases related to the activity of IL-17A.[French]
La présente invention concerne des immunomodulateurs. Plus particulièrement, la présente invention concerne des composés qui inhibent l'IL-17A et leur utilisation en tant qu'immunomodulateurs dans la préparation de médicaments. La présente invention concerne l'utilisation de composés représentés par la formule (I) ou des stéréoisomères de ceux-ci dans la préparation de médicaments inhibant l'IL-17A, constituant ainsi une nouvelle option pour le criblage clinique et/ou la préparation de médicaments pour des maladies liées à l'activité de l'IL-17A.[Chinese]
本发明公开了一种免疫调节剂，具体涉及一类抑制IL-17A的化合物及其作为免疫调节剂在制备药物中的用途。本发明公开了式（I）所示的化合物、或其立体异构体在制备抑制IL-17A类药物中的用途，为临床上筛选和/或制备与IL-17A活性相关的疾病的药物提供了一种新的选择。